In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Prevalence prognostic impact of diabetes in heart failure with preserved, mid-range and reduced ejection fraction

Session Poster Session 3

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : SY Jang (Daegu,KR), BE Park (Daegu,KR), YJ Park (Daegu,KR), MH Bae (Daegu,KR), JH Lee (Daegu,KR), DH Yang (Daegu,KR), HS Park (Daegu,KR), Y Cho (Daegu,KR), SC Chae (Daegu,KR)

SY Jang1 , BE Park1 , YJ Park1 , MH Bae1 , JH Lee1 , DH Yang1 , HS Park1 , Y Cho1 , SC Chae1 , 1Kyungpook National University Hospital - Daegu - Korea (Republic of) ,

On behalf: KorAHF registry investigators



Diabetes is common comorbid condition in patients with heart failure and worsens the prognosis of the patients. Prevalence and prognostic impact of diabetes on the heart failure patients with preserved (HFpEF), mid-range (HFmrEF) and reduced ejection fraction (HFrEF) is not well known. This study was aimed to investigate the prevalence and clinical impact of diabetes depending on heart failure subtypes of HFpEF, HFmrEF, and HFrEF.


From Korean acute heart failure registry, 5,116 in-hospital survivors were included in the present study. Prevalence and clinical impact of diabetes were evaluated according to the subgroups divided by ejection fraction (EF) <40%, 40-49%, and =50%. Composite event of all-cause mortality and hospitalization for heart failure was analyzed as prognosis using Cox proportional hazard model.


Among the study population, 25.7% had HFpEF, 16.5% had HFmrEF, and 57.8% had HFpEF. During 1-year follow-up, 50.1% of composite event were observed. Adverse event rates of each subgroup were 17.6%, 15.9%, and 19.1%, which was not significantly different among the three groups (p=0.089). Prevalence of diabetes in HFpEF, HFmrEF, and HFrEF were 33.8%, 38.8%, and 41.5%, respectively (p<0.001). Diabetes was more frequently observed in patients with lower EF. Diabetes was not significantly associated with worse outcome In HFpEF (hazard ratio [HR] 1.215 [0.996-1.482], p=0.055), whereas diabetes was significantly related to worse outcome in HFmrEF (HR 1.332 [1.032-1.718], p=0.027) and HFrEF (HR 1.368 [1.212-1.543], p<0.001). After multivariable adjustment, diabetes remained as an independent risk factor in patients with HFrEF (HR 1.199 [1.054-1.364], p=0.006). However, the relation was weak in HFpEF (HR 1.11 [0.898-1.372], p=0.335) and HFmrEF (HR 1.128 [0.852-1.492], p=0.401).


In patients with heart failure, diabetes was more frequently observed as EF decreased. Diabetes was associated with worse clinical outcome especially in patients with HFrEF increasing adverse event risk by 20%, whereas the association was weaker in HFpEF and HFmrEF.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are